Addressing Resistant Pseudomonas aeruginosa Infections
Pranita D. Tamma, MD, MHS, discusses the approach to the clinical care and management of patients with gram-negative resistant Pseudomonas aeruginosa infections and the latest data supporting these decisions.
EP. 2: Determining Resistance Patterns in Difficult-to-Treat Resistant Pseudomonas Infections
August 5th 2025Results from a recent study comparing ceftolozane/tazobactam and ceftazidime/avibactam for difficult-to-treat Pseudomonas aeruginosa infections found no statistically significant difference in resistance emergence but a surprising numerical trend favoring ceftazidime/avibactam. Pranita Tamma, MD, MHS, continues her conversation about this topic.
Watch
EP. 3: Statistical Weighting Helps Reduce Bias in Observational Studies
August 15th 2025Pranita Tamma, MD, MHS, continues her conversation around a study she was involved in that compared ceftolozane–tazobactam and ceftazidime–avibactam. She discusses the usage of inverse probability weighting with propensity scores to balance patient groups and limit bias.
Watch
